Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Incyte (INCY) PT Lowered to $60 at RBC Capital
May 1, 2024 6:30 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $60.00 (from $65.00) while maintaining a Sector Perform rating.
The analyst comments "On the surface, some choppiness for the key commercial franchises; Opzelura dynamics seem to be improving with the... More
Incyte (INCY) PT Lowered to $52 at BMO Capital
April 30, 2024 4:29 PM EDTBMO Capital analyst Evan David Seigerman lowered the price target on Incyte (NASDAQ: INCY) to $52.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "Share response (-2%) follows a disappointing print, negative investor sentiment reflected in shares... More
